A phase 3, randomized, open-label study evaluating DN-101 in combination with docetaxel in androgen-independent prostate cancer (AIPC) (ASCENT-2).
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Calcitriol (Primary) ; Docetaxel (Primary) ; Dexamethasone; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASCENT-2
- Sponsors Transcept Pharmaceuticals Inc
- 09 May 2012 Additional trial locations added as reported by German Clinical Trials Register record.
- 09 May 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003880).
- 11 Apr 2011 Results published in the Journal of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History